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In this overview, we discuss the role of class II-associated invariant chain peptide (CLIP) in acute myeloid leukemia (AML),
one of the few tumors expressing HLA class II. The clinical impact, function and regulation of CLIP expression on leukemic
cells is addressed, indicating its potential as immunotherapeutic target in AML.
Several immunotherapeutic strategies are
currently available or tested to trigger the
immune system against tumor cells in
cancer patients. In this respect, the capa-
city of tumor cells to affect or escape from
T cell immunity should be taken into
consideration for the success of immu-
notherapy. Until now, many immune
escape mechanisms have been demon-
strated in tumor cells that interfere with
T cell function, such as the production
of immunosuppressive cytokines and the
inhibition of T cell-induced apoptosis.
The first requirement for interaction
between tumor cells and T cells is effici-
ent antigen presentation. Defects in the
HLA class I (HLA-I) antigen presentation
pathway are frequently seen in tumor
cells, but less is reported on HLA class
II (HLA-II) antigen presentation as
most tumors lack expression of HLA-II
and costimulatory molecules. However,
leukemic cells of patients with acute
myeloid leukemia (AML) do express these
molecules, suggesting that HLA-II antigen
presentation plays a role in T cell immu-
nity for this type of tumor.
We recently provided evidence that the
presentation of the class II-associated
invariant chain peptide (CLIP) on leuke-
mic cells can serve as an immune escape
mechanism in AML by disturbing the
activation of tumor-reactive CD4
+ T cells.
1
Separation of both CLIP
- and CLIP
+
leukemic cells from the same untreated
AML patients made it possible to exa-
mine the effect of CLIP expression on
the function of autologous CD4
+ T cells.
CD4
+ T cells cultured with CLIP
- leuke-
mic cells showed stronger activation,
increased polarization toward Th1 and
effector memory cells, and higher antigen-
specificity as compared with CD4
+ T cells
from CLIP
+ cocultures.
The detrimental impact of CLIP with
regard to CD4
+ T cell function fits with
previous observations that high expres-
sion of CLIP on leukemic cells at diagnosis
is associated with a high relapse risk and
poor survival in AML.
2 To explain the
underlying mechanism of this effect, one
could refer to studies using HLA-II-
transfected tumor cells. In the absence
of the precursor of CLIP, the invariant
chain (Ii), these tumor cells have increased
ability to present endogenous antigens
and activate tumor-specific CD4
+ T cells.
3
Because Ii classically binds to HLA-II
molecules in the endoplasmic reticulum
to block premature binding of endogen-
ous antigens and mediate their transport
to endosomal compartments,
4 a possible
explanation may be that CLIP on leuke-
mic cells indicates reduced presentation of
potentially leukemia-associated endogenous
antigens on HLA-II molecules. In one
AML patient, it was shown that antigen-
specific CD4
+ T cells from CLIP
-
cocultures responded to CLIP
- leukemic
cells, but not to CLIP
+ leukemic cells
and monocytes.
1 Moreover, in CLIP
-
leukemic cell lines, HLA-II processing
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Figure1. For figure legend, see page 213.
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was independent of Ii and relied on the
proteasome and transporter associated
with antigen processing (TAP),
5 two
mediators of endogenous antigen proces-
sing for HLA-I molecules. Most interest-
ingly, abundance of CLIP on primary
leukemic cells was also found for a
specific subtype of HLA-II
- AML, acute
promyelocytic leukemia.
6 Further analysis
of this HLA-II-unrelated association of
CLIP in leukemic cells revealed that it
promiscuously bound to HLA-I mole-
cules as well (submitted for publication),
predominantly in TAP-deficient cells.
This suggests additional involvement of
CLIP in aberrant HLA-I antigen pre-
sentation and escape from CD8
+ cyto-
toxic T cell (CTL)-mediated eradication.
In either way, CLIP on leukemic cells
probably contributes to a leukemia-
protective T cell environment leading to
outgrowth of AML. Since the presence
of CLIP on residual leukemic cells at
follow-up is associated with increased
relapse risk in AML (submitted for publi-
cation), CLIP also seems to be involved in
T cell immunity following first induction
chemotherapy and is thus a promising
target for immunotherapeutic intervention
to prevent disease recurrence.
In Figure1, a model is illustrated to
show the potential influence of CLIP
expression by leukemic cells on AML
immunopathogenesis and on currently
developed immunotherapeutic approaches
to introduce anti-leukemic T cell immu-
nity in AML, including dendritic cell
(DC) vaccination and adoptive T cell
transfer.
7,8 In patients with CLIP
- AML,
leukemic cells should be well-recognized
by presenting leukemia-associated anti-
gens (LAAs) to CD4
+ T cells or CTLs
(Fig.1A). This then initiates a potential
feed-forward loop wherein exogenous
antigens are internalized by DCs and
presented for priming of leukemia-specific
T cells. Only leukemia-specific priming
of T cells might be suboptimal in these
patients, which makes for example vac-
cination with LAA-loaded DCs a potential
treatment option. However, in CLIP
+
AML, CLIP on leukemic cells indicates
deficient presentation of endogenous
LAAs. This can put the feed-forward loop
on hold, either directly by preventing
their detection and eradication by T cells,
or indirectly by creating an immunosup-
pressive environment that causes DC or
T cell inactivation (Fig.1B). Administra-
tion of ex vivo generated LAA-loaded DC
vaccines or leukemia-specific T cells to
these patients may establish LAA presenta-
tion to stimulate T cell priming.
9 Still, it
does not deal with CLIP expressed by
leukemic cells that results in low immu-
nogenicity and direct impairment of T
cells (Fig.1C). To circumvent this, addi-
tional immunotherapeutic strategies need
to be included in current protocols that
down-modulate CLIP in vivo (Fig.1D).
As a result, LAA presentation on HLA-I
and HLA-II molecules might be simulta-
neously enhanced leading to effective T
cell immunity against leukemic cells. One
strategy may be to enhance the processing
machinery of endogenous antigens, such
as the stimulation of proteasomal and
TAP function by histone deacetylase
inhibitors (HDACi).
10 The design of
approaches that target the immune escape
mechanisms used by leukemic cells to
inhibit T cell activation could have great
promise for future active immunotherapy
in AML.
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Figure1 (see opposite page). The potential role of CLIP in AML immunopathogenesis and immunotherapy. Situations before and after immunotherapy
in patients with AML are proposed: (A) Tumor immunity in untreated CLIP
- AML; LAA-specific T cell priming and recognition are optimal due to enhanced
endogenous LAA presentation by leukemic cells. (B) Tumor immune escape in untreated CLIP
+ AML; leukemia-specific T cell priming as well as
recognition are hampered because of inhibition of DC function and low immunogenicity by CLIP
+ leukemic cells. (C) Tumor immune escape in treated
CLIP
+ AML; although priming of leukemia-specific T cells is resolved by DC vaccination or T cell transfer, leukemic cells still escape their recognition by
expressing CLIP. (D) Tumor immunity in treated CLIP
+ AML; by using DC vaccination or T cell transfer in combination with in vivo immunomodulatory
drugs, both T cell priming and recognition are targeted, which might induce a potent immune response against leukemic cells.
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